Physicochemical Properties
| Molecular Formula | C26H23BRN2O2 |
| Molecular Weight | 475.38 |
| Appearance | Light yellow to yellow solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | GluN2B-NMDAR antagonist-1 (Compound Z25) at 0.05 μM, 0.5 μM, and 5 μM demonstrated neuroprotection percentages of 35.7%, 48.8%, and 55.8% against NMDA-induced cell injury in SH-SY5Y cells [1]. In SH-SY5Y cells, the NMDA (500 μM)-induced Ca2+ influx is lessened by GluN2B-NMDAR antagonist-1 (5 μM) [1]. In SH-SY5Y cells, GluN2B-NMDAR antagonist-1 (0.05–5 μM, 6 h) amplifies the NMDA-induced down-regulation of p-ERK1/2 expression [1]. With a half-life value of more than 289.1 minutes, GluN2B-NMDAR antagonist-1 has good plasma stability [1]. |
| ln Vivo | GluN2B-NMDAR antagonist-1 (Compound Z25) (20–80 mg/kg, gavage), enhances mice's cognitive function in the ICV-ET1-induced vascular dementia mouse model [1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: SH-SY5Y cells Tested Concentrations: 0.05, 0.5, 5 μM Incubation Duration: 6 h Experimental Results: Increased NMDA-induced down-regulation of p-ERK1/2 expression, and reached the same level as Ifenprodil at 0.5 μM. |
| Animal Protocol |
Animal/Disease Models: ICV-ET1-induced vascular dementia mice model[1] Doses: 20, 40, and 80 mg/kg Route of Administration: intragastric (po) administration, daily. Experimental Results: diminished escape latency and swimming distance. Animal/Disease Models: Mouse (PK Assay) [1] Doses: iv (1 mg/kg) and po (10 mg/kg) Route of Administration: iv, po Experimental Results: pharmacokinetic/PK profile of Nemvaleukin alfa. dose (mg/kg) T1/2 (h) Cmax (ng/mL ) Cl (mL/min/kg) F% po (10 mg/kg) 1.11 181.7 3.12 iv (1 mg/kg) 0.67 1913 20.45 |
| References |
[1]. Discovery of novel tryptamine derivatives as GluN2B subunit-containing NMDA receptor antagonists via pharmacophore-merging strategy with orally available therapeutic effect of cerebral ischemia. Eur J Med Chem. 2023 May 5;253:115318. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1036 mL | 10.5179 mL | 21.0358 mL | |
| 5 mM | 0.4207 mL | 2.1036 mL | 4.2072 mL | |
| 10 mM | 0.2104 mL | 1.0518 mL | 2.1036 mL |